tapewire.
TapewireFind a company

organization · Reporting owner

COLUMN GROUP II, LP

Disclosed activity across 8 companies

Tapewire entity
84819
SEC CIK
0001600420

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Gritstone bio, Inc.GRTS · Entity 8094610% ownerOctober 02, 2018October 02, 2018
NGM BIOPHARMACEUTICALS INCNGM · Entity 1199710% ownerApril 05, 2024April 08, 2024
Oric Pharmaceuticals, Inc.ORIC · Entity 476510% ownerNovember 12, 2021November 16, 2021
eFFECTOR Therapeutics, Inc.EFTR · Entity 8991610% ownerAugust 25, 2021September 07, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Gritstone bio, Inc.

Report date October 02, 2018 · Filed October 02, 2018

Jointly reported with Column Group II GP, LP, Svennilson Peter, GOEDDEL DAVID V

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect3,102,934 Reported balance After 2018-10-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-10-02 · Conversion · Acquired 3,102,934 · Balance 3,102,934

F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Series A Convertible Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-10-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · 2018-10-02 · Conversion · Disposed 2,173,912 · Balance 0

F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Series B Convertible Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-10-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · 2018-10-02 · Conversion · Disposed 929,022 · Balance 0

F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F2: The Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and had no expiration date.

F3: The shares are directly held by The Column Group II, LP and indirectly held by The Column Group II GP, LP, the general partner of The Column Group II, LP. The managing partners of The Column Group II GP, LP are David Goeddel and Peter Svennilson. The managing partners of The Column Group II GP, LP may be deemed to have shared voting and investment power with respect to the shares. Each individual managing partner disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.

NGM BIOPHARMACEUTICALS INC

Report date April 05, 2024 · Filed April 08, 2024

Jointly reported with COLUMN GROUP L P, Svennilson Peter, Kutzkey Tim, Ponoi Capital II, LP, Ponoi II Management, LLC, PONOI CAPITAL, LP, Ponoi Management, LLC, Column Group Management LP, Column Group II GP, LP

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee footnotes0 Reported balance After 2024-04-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-04-05 · Disposition to issuer · Disposed 949,862 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)

F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2024-04-05 · Disposition to issuer · Disposed 2,650,177 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2024-04-05 · Disposition to issuer · Disposed 90,442 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2024-04-05 · Disposition to issuer · Disposed 858,035 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2024-04-05 · Disposition to issuer · Disposed 968,990 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2024-04-05 · Disposition to issuer · Disposed 2,265,758 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 8 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 9 · 2024-04-05 · Disposition to issuer · Disposed 1,298,908 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 10 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 11 · 2024-04-05 · Disposition to issuer · Disposed 100,000 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 12 · 2024-04-05 · Disposition to issuer · Disposed 15,000 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F15: The securities were owned solely by Tim Kutzkey.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-04-05 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 13 · 2024-04-05 · Disposition to issuer · Disposed 44,000 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F16: The securities were directly held by Peter Svennilson.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,000 Reported balance After 2024-04-05 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 14 · 2024-04-05 · Other · Acquired 1,000 · Balance 1,000

F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2024-04-05 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2024-04-05 · Disposition to issuer · Disposed 11,103,333 · Balance 0

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Filing footnotes · ownership attribution and instrument terms

F1: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F3: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)

F4: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F7: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F8: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F9: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F10: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F11: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F12: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F13: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F14: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F15: The securities were owned solely by Tim Kutzkey.

F16: The securities were directly held by Peter Svennilson.

F17: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

Oric Pharmaceuticals, Inc.

Report date November 12, 2021 · Filed November 16, 2021

Jointly reported with Column Group II GP, LP, GOEDDEL DAVID V, Svennilson Peter, Column Group LLC

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote16,625 Reported balance After 2021-11-12 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-11-12 · Exercise / conversion · Acquired 16,625 · Balance 16,625

F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.

Common StockSEC Table I · non-derivativeIndirectSee Footnote287,702 Reported balance After 2021-11-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2021-11-16 · Other · Acquired 287,702 · Balance 287,702

F4: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.

F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2021-11-16 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2021-11-16 · Other · Disposed 287,702 · Balance 0

F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners.

F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote86,716 Reported balance After 2021-11-16 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 5 · 2021-11-16 · Other · Acquired 86,716 · Balance 86,716

F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F8: These securities are directly held by David Goeddel.

Common StockSEC Table I · non-derivativeIndirectSee Footnote103,341 Reported balance After 2021-11-16 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 6 · 2021-11-16 · Other · Acquired 86,716 · Balance 103,341

F9: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.

Common StockSEC Table I · non-derivativeIndirectSee Footnote74 Reported balance After 2021-11-16 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 7 · 2021-11-16 · Other · Acquired 74 · Balance 74

F10: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F11: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeDirect3,568,181 Reported balance After 2021-11-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2021-11-16 · Other · Disposed 1,200,000 · Balance 3,568,181

F2: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.

F3: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2031-06-15IndirectSee Footnote0 Reported balance After 2021-11-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2021-11-12 · Exercise / conversion · Disposed 16,625 · Balance 0

F12: As of the transaction date, 16,625 of the shares subject to this option have vested.

F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.

F13: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are directly held by Peter Svennilson. Peter Svennilson is a former member of the Issuer's board of directors and previously filed his own Section 16 reports reporting his holdings.

F2: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.

F3: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to have voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partner disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares in the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.

F5: The securities are directly held by TCG II GP. The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each individual TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F6: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its partners.

F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F8: These securities are directly held by David Goeddel.

F9: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F10: Represents a change in the form of ownership of The Column Group, LLC ("TCG LLC") by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F11: These securities are directly held by TCG LLC. The managing members of TCG LLC are the TCG II GP Managing Partners and Timothy Kutzkey (collectively, the "TCG LLC Managing Partners"). The TCG LLC Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG LLC and each of the TCG LLC Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F12: As of the transaction date, 16,625 of the shares subject to this option have vested.

F13: The option was granted to Peter Svennilson for his service as a member of the Issuer's board of directors.

eFFECTOR Therapeutics, Inc.

Report date August 25, 2021 · Filed September 07, 2021

Jointly reported with Column Group II GP, LP, Svennilson Peter, GOEDDEL DAVID V

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeIndirectSee Footnote4,309,329 Reported balance Holding disclosure · report date 2021-08-25 · row 1 Holding and transaction disclosures are not merged.
1 source row

Row 1 · Balance 4,309,329

F1: On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR" and "Issuer"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer.

F2: Represents 4,109,329 shares of the Issuer's common stock received in connection with the Merger and 200,000 shares of the Issuer's common stock that were acquired in a private placement which closed concurrently with the Merger.

F3: The securities are directly held by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On August 25, 2021, pursuant to that certain Agreement and Plan of Merger, dated as of May 26, 2021 (the "Merger Agreement"), by and among the Issuer (f/k/a Locust Walk Acquisition Corp.), Locust Walk Merger Sub, Inc. ("Merger Sub"), and eFFECTOR Therapeutics, Inc. ("Old eFFECTOR" and "Issuer"), Merger Sub merged with and into Old eFFECTOR with Old eFFECTOR surviving as a wholly owned subsidiary of the Issuer (the "Merger"). Upon consummation of the Merger (the "Effective Time"), each issued and outstanding share of common stock of Old eFFECTOR was automatically cancelled and converted into approximately 0.09657 (the "Exchange Ratio") shares of common stock of the Issuer.

F2: Represents 4,109,329 shares of the Issuer's common stock received in connection with the Merger and 200,000 shares of the Issuer's common stock that were acquired in a private placement which closed concurrently with the Merger.

F3: The securities are directly held by The Column Group II, LP ("TCG II LP"). The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Past disclosures · reporting ended (4)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Arcus Biosciences, Inc.

Report date March 19, 2018 · Filed March 19, 2018

Jointly reported with Column Group II GP, LP, Ponoi Management, LLC, PONOI CAPITAL, LP, GOEDDEL DAVID V, Svennilson Peter, Kutzkey Tim

Section 16 reporting ended · disclosed 2018-03-19. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,767,676 Reported balance After 2018-03-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2018-03-19 · Conversion · Acquired 1,767,676 · Balance 1,767,676

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

Common StockSEC Table I · non-derivativeDirect2,642,763 Reported balance After 2018-03-19 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 2 · 2018-03-19 · Conversion · Acquired 875,087 · Balance 2,642,763

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

Common StockSEC Table I · non-derivativeDirect3,070,423 Reported balance After 2018-03-19 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 3 · 2018-03-19 · Conversion · Acquired 427,660 · Balance 3,070,423

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

Common StockSEC Table I · non-derivativeDirect470,427 Reported balance After 2018-03-19 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 4 · 2018-03-19 · Conversion · Acquired 470,427 · Balance 470,427

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Series A Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-03-19 transaction · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · 2018-03-19 · Conversion · Disposed 1,767,676 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

Series B Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-03-19 transaction · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · 2018-03-19 · Conversion · Disposed 875,087 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-03-19 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2018-03-19 · Conversion · Disposed 427,660 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

Series C Preferred StockSEC Table II · derivative / convertible securityDirect0 Reported balance After 2018-03-19 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2018-03-19 · Conversion · Disposed 470,427 · Balance 0

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the closing of the Issuer's initial public offering of its common stock, each share of Series A, Series B and Series C preferred stock automatically converted into one share of common stock. The Series A, Series B and Series C preferred stock had no expiration date.

F2: The securities are directly held by The Column Group II, LP ("TCG II") and indirectly held by The Column Group II GP, LP ("TCG II GP") the general partner of TCG II. TCG II GP has voting and dispositive power with respect to these shares. The individual managing partners of TCG II GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares

F3: The securities are directly held by Ponoi Capital, LP ("Ponoi LP") and indirectly held by Ponoi Management, LLC ("Ponoi LLC") the general partner of Ponoi LP. Ponoi LLC has voting and dispositive power with respect to these shares. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting, investment and dispositive power with respect to these shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

IMMUNE DESIGN CORP.

Report date April 02, 2019 · Filed April 02, 2019

Jointly reported with COLUMN GROUP L P, COLUMN GROUP GP, LP, Column Group II GP, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, GOEDDEL DAVID V, Kutzkey Tim, Svennilson Peter

Section 16 reporting ended · disclosed 2019-04-02. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect0 Reported balance After 2019-04-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2019-04-02 · Other · Disposed 6,642,942 · Balance 0

F1: Includes shares directly held by Ponoi Capital LP ("Ponoi LP"), The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares.

F2: (cont.) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Includes shares directly held by Ponoi Capital LP ("Ponoi LP"), The Column Group II, LP ("TCG II LP") and The Column Group, LP ("TCG LP"). The Column Group II GP, LP ("TCG II GP"), as the general partner of TCG II LP, has voting and dispositive power with respect to certain of the shares. The Column Group GP, LP ("TCG GP"), as the general partner of TCG LP, has voting and dispositive power with respect to certain of the shares. Ponoi Management, LLC ("Ponoi LLC"), as the general partner of Ponoi LP, has voting and dispositive power with respect to certain of the shares.

F2: (cont.) The individual managing partners of both TCG II GP and TCG GP are Peter Svennilson and David Goeddel, who may be deemed to have shared voting and dispositive power with respect to the shares owned by TCG II LP and TCG LP. The individual managing partners of Ponoi LLC are Peter Svennilson, David Goeddel and Tim Kutzkey, who may be deemed to have shared voting and dispositive power with respect to the shares owned by Ponoi LP. Each individual managing partner disclaims beneficial ownership of the shares, except to the extent of his pecuniary interest in such shares.

Nurix Therapeutics, Inc.

Report date May 07, 2021 · Filed May 07, 2021

Jointly reported with COLUMN GROUP L P, COLUMN GROUP GP, LP, Column Group II GP, LP, PONOI CAPITAL, LP, Ponoi Management, LLC, Ponoi II Management, LLC, Ponoi Capital II, LP, Kutzkey Tim, GOEDDEL DAVID V

Section 16 reporting ended · disclosed 2021-05-07. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect1,394,333 Reported balance After 2021-05-05 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2021-05-05 · Other · Disposed 2,000,000 · Balance 1,394,333

F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners.

F2: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote438,338 Reported balance After 2021-05-05 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2021-05-05 · Other · Acquired 438,338 · Balance 438,338

F3: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote10,307 Reported balance After 2021-05-05 transaction · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307

F5: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F6: The securities are directly held by Peter Svennilson

Common StockSEC Table I · non-derivativeIndirectSee Footnote10,307 Reported balance After 2021-05-05 transaction · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307

F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F8: The securities are directly held by David Goeddel.

Common StockSEC Table I · non-derivativeIndirectSee Footnote10,307 Reported balance After 2021-05-05 transaction · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · 2021-05-05 · Other · Acquired 10,307 · Balance 10,307

F9: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F10: The securities are directly held by Tim Kutzkey.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2021-05-05 transaction · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · 2021-05-05 · Other · Disposed 438,338 · Balance 0

F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners.

F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote116,181 Reported balance After 2021-05-05 transaction · row 7 Holding and transaction disclosures are not merged.
1 source row

Row 7 · 2021-05-05 · Other · Acquired 105,874 · Balance 116,181

F12: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F6: The securities are directly held by Peter Svennilson

Common StockSEC Table I · non-derivativeIndirectSee Footnote121,554 Reported balance After 2021-05-05 transaction · row 8 Holding and transaction disclosures are not merged.
1 source row

Row 8 · 2021-05-05 · Other · Acquired 111,247 · Balance 121,554

F13: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F8: The securities are directly held by David Goeddel.

Common StockSEC Table I · non-derivativeIndirectSee Footnote40,654 Reported balance After 2021-05-05 transaction · row 9 Holding and transaction disclosures are not merged.
1 source row

Row 9 · 2021-05-05 · Other · Acquired 30,347 · Balance 40,654

F14: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F10: The securities are directly held by Tim Kutzkey.

Common StockSEC Table I · non-derivativeIndirectSee Footnote989,000 Reported balance After 2021-05-05 transaction · row 10 Holding and transaction disclosures are not merged.
1 source row

Row 10 · 2021-05-05 · Other · Disposed 1,000,000 · Balance 989,000

F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.

F16: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote49,689 Reported balance After 2021-05-05 transaction · row 11 Holding and transaction disclosures are not merged.
1 source row

Row 11 · 2021-05-05 · Other · Acquired 49,689 · Balance 49,689

F17: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.

F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote0 Reported balance After 2021-05-05 transaction · row 12 Holding and transaction disclosures are not merged.
1 source row

Row 12 · 2021-05-05 · Other · Disposed 49,689 · Balance 0

F19: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners.

F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote134,010 Reported balance After 2021-05-05 transaction · row 13 Holding and transaction disclosures are not merged.
1 source row

Row 13 · 2021-05-05 · Other · Acquired 17,829 · Balance 134,010

F20: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F6: The securities are directly held by Peter Svennilson

Common StockSEC Table I · non-derivativeIndirectSee Footnote139,383 Reported balance After 2021-05-05 transaction · row 14 Holding and transaction disclosures are not merged.
1 source row

Row 14 · 2021-05-05 · Other · Acquired 17,829 · Balance 139,383

F21: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F8: The securities are directly held by David Goeddel.

Common StockSEC Table I · non-derivativeIndirectSee Footnote48,406 Reported balance After 2021-05-05 transaction · row 15 Holding and transaction disclosures are not merged.
1 source row

Row 15 · 2021-05-05 · Other · Acquired 7,752 · Balance 48,406

F22: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F10: The securities are directly held by Tim Kutzkey.

Common StockSEC Table I · non-derivativeIndirectSee Footnote686,274 Reported balance Holding disclosure · report date 2021-05-07 · row 16 Holding and transaction disclosures are not merged.
1 source row

Row 16 · Balance 686,274

F23: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee Footnote686,274 Reported balance Holding disclosure · report date 2021-05-07 · row 17 Holding and transaction disclosures are not merged.
1 source row

Row 17 · Balance 686,274

F24: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group, LP ("TCG LP") to its general and limited partners.

F2: The securities are directly held by TCG LP, and indirectly held by The Column Group GP, LP ("TCG GP"), the general partner of TCG LP. The managing partners of TCG GP are David Goeddel and Peter Svennilson (the "Managing Partners"). The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F3: Represents a change in the form of ownership of TCG GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F4: The securities are directly held by TCG GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F5: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F6: The securities are directly held by Peter Svennilson

F7: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F8: The securities are directly held by David Goeddel.

F9: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG LP.

F10: The securities are directly held by Tim Kutzkey.

F11: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG GP to its general and limited partners.

F12: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F13: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F14: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG GP.

F15: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by The Column Group II, LP ("TCG II LP") to its general and limited partners.

F16: The securities are directly held by TCG II LP, and indirectly held by The Column Group II GP, LP ("TCG II GP"), the general partner of TCG II LP. The managing partners of TCG II GP are the Managing Partners. The Managing Partners may be deemed to have voting and investment power with respect to such shares. Each individual Managing Partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F17: Represents a change in the form of ownership of TCG II GP by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II LP.

F18: The securities are directly held by TCG II GP. The Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F19: Represents a pro-rata distribution, and not a purchase or sale, without additional consideration by TCG II GP to its general and limited partners.

F20: Represents a change in the form of ownership of Peter Svennilson by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F21: Represents a change in the form of ownership of David Goeddel by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F22: Represents a change in the form of ownership of Tim Kutzkey by virtue of the receipt of shares as a result of the pro-rata in-kind distribution of common stock of the Issuer for no consideration by TCG II GP.

F23: The securities are directly held by Ponoi Capital, LP ("Ponoi LP"), and indirectly held by Ponoi Management, LLC ("Ponoi LLC"), the general partner of Ponoi LP. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

F24: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"), and indirectly held by Ponoi II Management, LLC ("Ponoi II LLC"), the general partner of Ponoi II LP. The managing partners of Ponoi II LLC are David Goeddel, Peter Svennilson and Tim Kutzkey. The managing partners of Ponoi II LLC may be deemed to have voting and investment power with respect to such shares. Each individual managing partner disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest in such shares.

RAPT Therapeutics, Inc.

Report date December 23, 2024 · Filed December 23, 2024

Jointly reported with Column Group IV, LP, Column Group IV-A, LP, Column Group IV GP, LP, TCG IV GP, LLC

Section 16 reporting ended · disclosed 2024-12-23. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect50,000 Reported balance After 2024-12-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source row

Row 1 · 2024-12-23 · Other · Disposed 1,352,008 · Balance 50,000

F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote0 Reported balance After 2024-12-23 transaction · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · 2024-12-23 · Other · Disposed 1,599,417 · Balance 0

F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote1,236,261 Reported balance Holding disclosure · report date 2024-12-23 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 1,236,261

F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote42,189 Reported balance Holding disclosure · report date 2024-12-23 · row 4 Holding and transaction disclosures are not merged.
1 source row

Row 4 · Balance 42,189

F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Common StockSEC Table I · non-derivativeIndirectSee footnote163 Reported balance Holding disclosure · report date 2024-12-23 · row 5 Holding and transaction disclosures are not merged.
1 source row

Row 5 · Balance 163

F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Common StockSEC Table I · non-derivativeIndirectSee footnote145,401 Reported balance Holding disclosure · report date 2024-12-23 · row 6 Holding and transaction disclosures are not merged.
1 source row

Row 6 · Balance 145,401

F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00Direct1,352,008 Reported balance After 2024-12-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 7 · 2024-12-23 · Other · Acquired 1,352,008 · Balance 1,352,008

F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00IndirectSee footnote1,599,417 Reported balance After 2024-12-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 8 · 2024-12-23 · Other · Acquired 1,599,417 · Balance 1,599,417

F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Filing footnotes · ownership attribution and instrument terms

F1: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F2: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F3: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F4: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F5: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

F6: The securities are directly held The Column Group LLC ("TCG LLC"). The managing members of TCG LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F7: The securities are directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi II LLC are the Ponoi Managing Partners. The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi II LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

F8: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
December 23, 2024 Filed Dec 23, 2024 17:59 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 OtherWarrant (right to purchase) · Derivative 1,599,417 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000950170-24-139755 · ownership.xml · derivative · entry 8

COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner

Column Group IV, LP · CIK 0001796354 · 10% owner

Column Group IV-A, LP · CIK 0001796353 · 10% owner

Column Group IV GP, LP · CIK 0001796356 · 10% owner

TCG IV GP, LLC · CIK 0001796359 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,599,417

Underlying: Common Stock · 1,599,417 shares

Expires not disclosed

F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F8 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F8 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F3 · ownership.nature: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Read SEC document
December 23, 2024 Filed Dec 23, 2024 17:59 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 OtherWarrant (right to purchase) · Derivative 1,352,008 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000950170-24-139755 · ownership.xml · derivative · entry 7

COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner

Column Group IV, LP · CIK 0001796354 · 10% owner

Column Group IV-A, LP · CIK 0001796353 · 10% owner

Column Group IV GP, LP · CIK 0001796356 · 10% owner

TCG IV GP, LLC · CIK 0001796359 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,352,008

Underlying: Common Stock · 1,352,008 shares

Expires not disclosed

F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F8 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F8 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F2 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Read SEC document
December 23, 2024 Filed Dec 23, 2024 17:59 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 OtherCommon Stock 1,599,417 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-139755 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner

Column Group IV, LP · CIK 0001796354 · 10% owner

Column Group IV-A, LP · CIK 0001796353 · 10% owner

Column Group IV GP, LP · CIK 0001796356 · 10% owner

TCG IV GP, LLC · CIK 0001796359 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F3 · ownership.nature: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Read SEC document
December 23, 2024 Filed Dec 23, 2024 17:59 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 OtherCommon Stock 1,352,008 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-139755 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner

Column Group IV, LP · CIK 0001796354 · 10% owner

Column Group IV-A, LP · CIK 0001796353 · 10% owner

Column Group IV GP, LP · CIK 0001796356 · 10% owner

TCG IV GP, LLC · CIK 0001796359 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F2 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Read SEC document
December 23, 2024 Filed Dec 23, 2024 17:57 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 OtherWarrant (right to purchase) · Derivative 1,599,417 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000950170-24-139754 · ownership.xml · derivative · entry 8

COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

GOEDDEL DAVID V · CIK 0001182464 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Column Group LLC · CIK 0001833486 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,599,417

Underlying: Common Stock · 1,599,417 shares

Expires not disclosed

F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F8 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F8 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F3 · ownership.nature: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Read SEC document
December 23, 2024 Filed Dec 23, 2024 17:57 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 OtherWarrant (right to purchase) · Derivative 1,352,008 Not disclosed Strike: $0.00 Not disclosed
Disclosure

SEC source: 0000950170-24-139754 · ownership.xml · derivative · entry 7

COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

GOEDDEL DAVID V · CIK 0001182464 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Column Group LLC · CIK 0001833486 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,352,008

Underlying: Common Stock · 1,352,008 shares

Expires not disclosed

F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F8 · derivative.exercise_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F8 · derivative.expiration_date: The Pre-Funded Warrant has no expiration date and is exercisable at any time after the date of issuance. Notwithstanding the foregoing, a holder of the Pre-Funded Warrant may not exercise the Pre-Funded Warrant if the holder, together with other persons whose beneficial ownership is aggregated for purposes of Section 13 or Section 16 under the Securities Exchange Act of 1934, as amended, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise.

F2 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Read SEC document
December 23, 2024 Filed Dec 23, 2024 17:57 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 OtherCommon Stock 1,599,417 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-139754 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

GOEDDEL DAVID V · CIK 0001182464 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Column Group LLC · CIK 0001833486 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F3 · ownership.nature: The securities are directly held by Ponoi LP. Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of Ponoi LLC are David Goeddel, Peter Svennilson and Tim Kutzkey (collectively, the "Ponoi Managing Partners"). The Ponoi Managing Partners may be deemed to share voting and investment power with respect to such shares. Ponoi LLC and the each of the Ponoi Managing Partners disclaims beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Read SEC document
December 23, 2024 Filed Dec 23, 2024 17:57 UTC RAPT Therapeutics, Inc. RAPT · Entity 62554 OtherCommon Stock 1,352,008 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-139754 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP II, LP · CIK 0001600420 · Former 10% Owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

GOEDDEL DAVID V · CIK 0001182464 · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Column Group LLC · CIK 0001833486 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,000

F1 · kind: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F1 · price: On December 23, 2024, The Column Group II, LP ("TCG II LP") and Ponoi Capital, LP ("Ponoi LP") entered into an exchange agreement with the Issuer pursuant to which TCG II LP and Ponoi LP exchanged, for no additional consideration, 1,352,008 and 1,599,417 shares of the Issuer's Common Stock, respectively, for a pre-funded warrant to purchase 1,352,008 and 1,599,417 shares of Common Stock, respectively (the "Pre-Funded Warrants"). The Pre-Funded Warrants were issued on December 23, 2024 and have an exercise price of $0.0001 per share.

F2 · ownership.direct: The securities are directly held by TCG II LP. The Column Group II GP, LP ("TCG II GP") is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are David Goeddel and Peter Svennilson (collectively, the "TCG II GP Managing Partners"). The TCG II GP Managing Partners may be deemed to share voting and investment power with respect to such shares. TCG II GP and each of the TCG II GP Managing Partners disclaim beneficial ownership of these shares, except to the extent of their respective pecuniary interest in such shares.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 OtherCommon Stock 1,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 14

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 1,000

F17 · price: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

F17 · ownership.nature: At the Effective Time, Purchaser merged with and into the Issuer pursuant to Section 251(h) of the Delaware General Corporation Law, with the Issuer surviving as a wholly-owned subsidiary of the Parent. As a result, Parent holds all of the issued and outstanding shares of common stock (equaling 1,000 shares) of the Issuer. TCG LP owns 28.1% of Parent and is the general partner of Parent. Peter Svennilson and Dr. Goeddel are the managing partners of TCG GP, which is the general partner of TCG LP.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 44,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 13

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F16 · ownership.nature: The securities were directly held by Peter Svennilson.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 15,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 12

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F15 · ownership.nature: The securities were owned solely by Tim Kutzkey.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 100,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 11

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F14 · ownership.nature: The securities were directly held by The Column Group Management LP ("TCGM LP"). The managing partners of TCGM LP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 100,000 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 10

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F13 · ownership.nature: The securities were directly held by TCG GP. The managing members of TCG GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. Each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 1,298,908 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 9

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F12 · ownership.nature: The securities were directly held by Ponoi Capital II, LP ("Ponoi II LP"). Ponoi II Management, LLC ("Ponoi II LLC") is the general partner of Ponoi II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi II LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi II LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 1,298,908 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 8

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F11 · ownership.nature: The securities were directly held by Ponoi Capital, LP ("Ponoi LP"). Ponoi Management, LLC ("Ponoi LLC") is the general partner of Ponoi LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of Ponoi LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. Ponoi LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 2,265,758 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 7

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F10 · ownership.nature: The securities were directly held by The Column Group II, LP ("TCG II LP"). TCG II GP is the general partner of TCG II LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG II GP are the TCG Managing Partners. The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG II GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 968,990 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 6

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F9 · ownership.nature: The securities were directly held by The Column Group III-A, LP ("TCG III-A LP"). TCG III GP is the general partner of TCG III-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 858,035 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 5

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F8 · ownership.nature: The securities were directly held by The Column Group III, LP ("TCG III LP"). The Column Group III GP, LP ("TCG III GP") is the general partner of TCG III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG III GP are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG III GP and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 11,103,333 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 4

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F7 · ownership.direct: The securities were directly held by The Column Group, LP ("TCG LP").The Column Group GP, LP ("TCG GP") is the general partner of TCG LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing partners of TCG GP are David Goeddel, a member of the Issuer's board of directors and Peter Svennilson (collectively, the "TCG Managing Partners"). The TCG Managing Partners may be deemed to share voting, investment and dispositive power with respect to such securities. TCG GP and each of the TCG Managing Partners disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 90,442 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 3

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F6 · ownership.nature: The securities were directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 2,650,177 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F5 · ownership.nature: The securities were directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG IV LLC are the TCG Managing Members. The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
April 05, 2024 Filed Apr 8, 2024 20:03 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 Disposition to issuerCommon Stock 949,862 Not disclosed Not disclosed
Disclosure

SEC source: 0000950142-24-001000 · eh240467034_4-ngm1.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 0

F1 · price: On February 25, 2024, the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser") entered into an Agreement and Plan of Merger, pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Concurrently with the execution of the Merger Agreement, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement with The Column Group, LP, The Column Group GP, LP, The Column Group Management, LP, The Column Group II, LP, The Column Group III, LP, The Column Group III-A, LP, The Column Group IV, LP, The Column Group IV-A, LP, The Column Group Opportunity III, LP, Ponoi Capital, LP and Ponoi Capital II, LP (the "TCG Rollover Agreement"). (cont'd in FN 2)

F2 · price: (cont'd from FN 1) In addition, Parent and Purchaser entered into a rollover agreement, dated as of the date of the Merger Agreement (supplemented by the joinder thereto), with certain of NGM's other stockholders, including Dr. Goeddel (the "Stockholder Rollover Agreement" and, together with the TCG Rollover Agreement, the "Rollover Agreements"). Pursuant to the Rollover Agreements, every 1 share of the Issuer subject to the Rollover Agreement was exchanged for 100 shares of Parent. This Form 4 reports securities disposed of pursuant to the Rollover Agreements.

F3 · ownership.nature: The securities were directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members"). (cont'd in FN 3)

F4 · ownership.nature: (cont'd from FN 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
November 16, 2023 Filed Nov 17, 2023 16:28 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 5,840 $0.62 $3,627.22
Disclosure

SEC source: 0000950170-23-064847 · ownership.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 949,862

F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.6198 to $0.6221, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
November 15, 2023 Filed Nov 17, 2023 16:28 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 16,791 $0.71 $11,879.63
Disclosure

SEC source: 0000950170-23-064847 · ownership.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 944,022

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.681 to $0.7201, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
January 31, 2023 Filed Feb 1, 2023 16:29 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 176,730 $5.00 $883,402.58
Disclosure

SEC source: 0000899243-23-003130 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 927,231

F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
January 30, 2023 Filed Feb 1, 2023 16:29 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 7,542 $5.00 $37,706.98
Disclosure

SEC source: 0000899243-23-003130 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 750,501

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.99 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
January 23, 2023 Filed Jan 25, 2023 16:31 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 9,900 $5.00 $49,494.06
Disclosure

SEC source: 0000899243-23-002630 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 742,959

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.995 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
January 20, 2023 Filed Jan 23, 2023 16:19 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 500 $5.00 $2,498.00
Disclosure

SEC source: 0000899243-23-002375 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 733,059

F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
January 19, 2023 Filed Jan 23, 2023 16:19 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 37,639 $5.00 $188,104.67
Disclosure

SEC source: 0000899243-23-002375 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 732,559

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.975 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
January 12, 2023 Filed Jan 17, 2023 16:32 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 5,378 $4.95 $26,602.81
Disclosure

SEC source: 0000899243-23-001854 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 694,920

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.77 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
January 11, 2023 Filed Jan 12, 2023 16:35 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 209,000 $4.76 $994,840.00
Disclosure

SEC source: 0000899243-23-001694 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 689,542

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
January 10, 2023 Filed Jan 12, 2023 16:35 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 100,070 $4.84 $484,518.93
Disclosure

SEC source: 0000899243-23-001694 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 480,542

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.70 to $4.98, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
December 12, 2022 Filed Dec 14, 2022 16:28 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 300 $4.98 $1,493.01
Disclosure

SEC source: 0000899243-22-038465 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 380,472

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.97 to $4.98, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
November 22, 2022 Filed Nov 23, 2022 16:14 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 4,330 $5.00 $21,646.10
Disclosure

SEC source: 0000899243-22-036912 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 380,172

F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
November 21, 2022 Filed Nov 23, 2022 16:14 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 35,997 $5.00 $179,941.80
Disclosure

SEC source: 0000899243-22-036912 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 375,842

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.98 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting, investment and dispositive power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting, investment and dispositive power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
November 04, 2022 Filed Nov 7, 2022 16:17 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 35,058 $4.72 $165,319.50
Disclosure

SEC source: 0000899243-22-035274 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 339,845

F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.30 to $4.99, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 4 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
November 03, 2022 Filed Nov 7, 2022 16:17 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 104,090 $4.99 $519,107.24
Disclosure

SEC source: 0000899243-22-035274 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 304,787

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.95 to $5.00, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
October 27, 2022 Filed Oct 31, 2022 17:17 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 76,877 $4.86 $373,637.60
Disclosure

SEC source: 0000899243-22-034559 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnotes

Disclosed balance after: 200,697

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.795 to $4.90, inclusive. The Reporting Persons undertake to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
October 26, 2022 Filed Oct 27, 2022 18:50 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 72,774 $4.85 $353,041.23
Disclosure

SEC source: 0000899243-22-034352 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 123,820

F4 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.795 to $4.95, inclusive. The Reporting Persons undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 3 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
October 25, 2022 Filed Oct 27, 2022 18:50 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 51,046 $4.75 $242,386.83
Disclosure

SEC source: 0000899243-22-034352 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 51,046

F1 · price: The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $4.705 to $4.80, inclusive. The Reporting Persons undertakes to provide to the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in this footnote 1 to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. TCG Opportunity III GP, LLC ("TCG Opportunity III GP LLC") is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG Opportunity III GP LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG Managing Members").

F3 · ownership.nature: (Continued from Footnote 2) The TCG Managing Members may be deemed to share voting and investment power with respect to such securities. TCG Opportunity III GP LP, TCG Opportunity III GP LLC and each of the TCG Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
June 09, 2022 Filed Jun 13, 2022 16:58 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 32,477 $13.50 $438,439.50
Disclosure

SEC source: 0000899243-22-022212 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 90,442

F2 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
June 09, 2022 Filed Jun 13, 2022 16:58 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 951,684 $13.50 $12,847,734.00
Disclosure

SEC source: 0000899243-22-022212 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,650,177

F1 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
June 02, 2022 Filed Jun 6, 2022 16:43 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 1,129 $13.03 $14,714.60
Disclosure

SEC source: 0000899243-22-021215 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 57,965

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.02 to $13.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
June 02, 2022 Filed Jun 6, 2022 16:43 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 33,071 $13.03 $431,024.26
Disclosure

SEC source: 0000899243-22-021215 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,698,493

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.02 to $13.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
June 01, 2022 Filed Jun 2, 2022 16:26 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 3,036 $13.45 $40,834.20
Disclosure

SEC source: 0000899243-22-020688 · doc4.xml · nonDerivative · entry 4

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 56,836

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.105 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
June 01, 2022 Filed Jun 2, 2022 16:26 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 88,964 $13.45 $1,196,565.80
Disclosure

SEC source: 0000899243-22-020688 · doc4.xml · nonDerivative · entry 3

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,665,422

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.105 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
May 31, 2022 Filed Jun 2, 2022 16:26 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 2,040 $13.47 $27,470.23
Disclosure

SEC source: 0000899243-22-020688 · doc4.xml · nonDerivative · entry 2

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 53,800

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.37 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
May 31, 2022 Filed Jun 2, 2022 16:26 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 59,766 $13.47 $804,797.00
Disclosure

SEC source: 0000899243-22-020688 · doc4.xml · nonDerivative · entry 1

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,576,458

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.37 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
May 27, 2022 Filed May 31, 2022 16:59 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 89 $13.45 $1,197.17
Disclosure

SEC source: 0000899243-22-020202 · doc4.xml · nonDerivative · entry 4

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 51,760

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.35 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F3 · ownership.nature: The securities are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. TCG IV LLC is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV-A LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are the TCG IV Managing Members. The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document
May 27, 2022 Filed May 31, 2022 16:59 UTC NGM BIOPHARMACEUTICALS INC NGM · Entity 11997 PurchaseCommon Stock 2,621 $13.45 $35,255.86
Disclosure

SEC source: 0000899243-22-020202 · doc4.xml · nonDerivative · entry 3

COLUMN GROUP L P · CIK 0001347769 · Director · 10% owner

Svennilson Peter · CIK 0001606074 · 10% owner

Kutzkey Tim · CIK 0001614186 · 10% owner · Managing Partner

Ponoi Capital II, LP · CIK 0001732601 · 10% owner

Ponoi II Management, LLC · CIK 0001746488 · 10% owner · General Partner

PONOI CAPITAL, LP · CIK 0001707230 · 10% owner

Ponoi Management, LLC · CIK 0001720702 · 10% owner · General Partner

COLUMN GROUP II, LP · CIK 0001600420 · 10% owner

Column Group Management LP · CIK 0001645340 · 10% owner

Column Group II GP, LP · CIK 0001645333 · 10% owner · General Partner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 1,516,692

F4 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.35 to $13.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of securities purchased at each separate price within the ranges set forth in this footnote (4) to this Form 4.

F2 · ownership.nature: The securities are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. TCG IV GP LLC ("TCG IV LLC") is the general partner of TCG IV GP LP and the ultimate general partner of TCG IV LP and may be deemed to have voting and investment power with respect to these securities. The managing members of TCG IV LLC are David Goeddel, a member of the issuer's board of directors, Peter Svennilson and Tim Kutzkey (collectively, the "TCG IV Managing Members"). The TCG IV Managing Members may be deemed to share voting and investment power with respect to such securities. TCG IV GP LP, TCG IV LLC and each of the TCG IV Managing Members disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interest in such securities.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.